{
  "docId": "019de076-0bfb-77a4-9766-824e83d61c36",
  "docSlug": "78f42e9d8d70fea2dc2370a17955f7e7",
  "documentTitle": "Nuvalent | Investor Presentation Deck | 52 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 47,
  "pageCount": 52,
  "prevPage": 46,
  "nextPage": 48,
  "slideType": "solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 15,
  "notes": "The slide uses three distinct chart types to demonstrate the drug's competitive advantage in a preclinical setting.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-0bfb-77a4-9766-824e83d61c36/47",
  "deckHref": "/decks/019de076-0bfb-77a4-9766-824e83d61c36",
  "deckJsonHref": "/decks/019de076-0bfb-77a4-9766-824e83d61c36.json",
  "deckAnchorHref": "/decks/019de076-0bfb-77a4-9766-824e83d61c36#slide-47",
  "components": [
    {
      "bbox": {
        "h": 0.55,
        "w": 0.31,
        "x": 0.39,
        "y": 0.22
      },
      "kind": "chart",
      "text": "AVOIDING EGFR INHIBITION",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "49613355-1f3a-4e84-8877-574f6c6df9fb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.21,
        "x": 0.72,
        "y": 0.22
      },
      "kind": "chart",
      "text": "BRAIN PENETRANCE",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c7f8d1b2-e218-4a49-9e22-e6eb7473e86e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.31,
        "x": 0.07,
        "y": 0.22
      },
      "kind": "chart",
      "text": "IN VITRO ACTIVITY, HER2 AND HER2ex20",
      "attrs": null,
      "subkind": "dot",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9f6ed1a0-74cf-4545-b5aa-1f477106b69a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.86,
        "x": 0.07,
        "y": 0.88
      },
      "kind": "disclaimer",
      "text": "IC50, half-maximal inhibitory concentration; PO, orally; Head-to-head clinical studies comparing NVL-330 with currently approved or investigational therapies have not been conducted. Above data from preclinical studies Source: Andrews K.L. et al., EORTC-NCI-AACR 2022.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f09d814e-52e3-4941-bc26-af17fca1805d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.86,
        "x": 0.07,
        "y": 0.06
      },
      "kind": "title",
      "text": "Preclinical | NVL-330 is a Brain Penetrant, HER2ex20-Selective Kinase Inhibitor with Potential to Avoid Adverse Events Related to EGFR Inhibition",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "abdb5ff8-9e97-4030-aacd-75aa220e3c4b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Chart Selection Guide",
      "slug": "chart-selection-guide",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "6ffab56d-b5d0-478b-8a6d-e72f32e7fb9f",
      "evidence": "IN VITRO ACTIVITY, HER2 AND HER2ex20, AVOIDING EGFR INHIBITION, BRAIN PENETRANCE",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}